Nektar Therapeutics (BMV:NKTR)

Market Cap	12.96B +292.7%
Revenue (ttm)	1.15B -32.8%
Net Income	-2.21B
EPS	-144.90
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5
Average Volume	108
Open	693.50
Previous Close	1,030.00
Day's Range	693.50 - 693.50
52-Week Range	165.00 - 1,135.00
Beta	n/a
RSI	49.14
Earnings Date	Feb 26, 2026

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution pro...

• Industry: Pharmaceutical Preparations
• Founded: 1990
• Employees: 61
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: NKTR

Financial Performance

In 2024, Nektar Therapeutics's revenue was $98.43 million, an increase of 9.22% compared to the previous year's $90.12 million. Losses were -$118.96 million, -56.91% less than in 2023.

Financial numbers in USD